Lisata Therapeutics, Inc.
LSTA
$5.03
-$0.01-0.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -90.00% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.00% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -90.00% | -- | -- | -- | -- |
| SG&A Expenses | -31.81% | -12.13% | -8.11% | -3.42% | -0.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.56% | -17.28% | -10.59% | -11.42% | -1.26% |
| Operating Income | 37.79% | 17.28% | 11.86% | 11.42% | 17.86% |
| Income Before Tax | 35.92% | 13.81% | 7.63% | 8.28% | 14.07% |
| Income Tax Expenses | -- | -- | -- | -20.55% | -- |
| Earnings from Continuing Operations | 35.92% | 13.81% | 7.63% | 12.53% | 14.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.92% | 13.81% | 7.63% | 12.53% | 14.07% |
| EBIT | 37.79% | 17.28% | 11.86% | 11.42% | 17.86% |
| EBITDA | 37.57% | 17.45% | 11.94% | 11.46% | 17.90% |
| EPS Basic | 38.88% | 17.92% | 10.82% | 15.66% | 16.66% |
| Normalized Basic EPS | 38.87% | 17.93% | 10.83% | 10.25% | 16.66% |
| EPS Diluted | 38.88% | 17.92% | 10.82% | 15.66% | 16.66% |
| Normalized Diluted EPS | 38.87% | 17.93% | 10.83% | 10.25% | 16.66% |
| Average Basic Shares Outstanding | 4.84% | 5.01% | 3.57% | 3.71% | 3.11% |
| Average Diluted Shares Outstanding | 4.84% | 5.01% | 3.57% | 3.71% | 3.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |